NASDAQ:CYTK - Cytokinetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.75 +0.05 (+0.57 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$8.75
Today's Range$8.50 - $8.80
52-Week Range$6.75 - $15.95
Volume170,522 shs
Average Volume342,947 shs
Market Capitalization$466.10 million
P/E Ratio-3.38
Dividend YieldN/A
Beta1.13

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics logoCytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Debt-to-Equity Ratio0.32
Current Ratio7.07
Quick Ratio7.07

Price-To-Earnings

Trailing P/E Ratio-3.38
Forward P/E Ratio-4.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.37 million
Price / Sales35.47
Cash FlowN/A
Price / CashN/A
Book Value$1.84 per share
Price / Book4.76

Profitability

EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net Margins-172.27%
Return on Equity-99.50%
Return on Assets-42.59%

Miscellaneous

Employees137
Outstanding Shares54,200,000

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics (NASDAQ:CYTK) issued its earnings results on Thursday, April, 26th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company earned $5.27 million during the quarter, compared to the consensus estimate of $5.50 million. Cytokinetics had a negative return on equity of 99.50% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

8 Wall Street analysts have issued twelve-month target prices for Cytokinetics' shares. Their forecasts range from $10.00 to $24.00. On average, they anticipate Cytokinetics' stock price to reach $15.75 in the next year. View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:
  • 1. Cantor Fitzgerald analysts commented, "Robert Califf, M.D. has joined CYTK’s Board of Directors (BoD), adding his expertise in cardiovascular and regulatory domains, we believe." (2/12/2018)
  • 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
  • 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)

Who are some of Cytokinetics' key competitors?

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)

Has Cytokinetics been receiving favorable news coverage?

News coverage about CYTK stock has trended somewhat positive on Thursday, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytokinetics earned a daily sentiment score of 0.21 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.67 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.44%), Wasatch Advisors Inc. (3.26%), Pinnacle Associates Ltd. (1.64%), Citigroup Inc. (1.43%), Principal Financial Group Inc. (0.73%) and Principal Financial Group Inc. (0.74%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc. and American International Group Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Millennium Management LLC, Employees Retirement System of Texas, A.R.T. Advisors LLC, UBS Group AG, JPMorgan Chase & Co., BlackRock Inc. and DRW Securities LLC. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $8.75.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $466.10 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (CYTK)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  412 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytokinetics (NASDAQ:CYTK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Cytokinetics in the last 12 months. Their average twelve-month price target is $15.75, suggesting that the stock has a possible upside of 80.00%. The high price target for CYTK is $24.00 and the low price target for CYTK is $10.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.892.90
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.75$15.75$16.7778$17.90
Price Target Upside: 80.00% upside118.75% upside116.49% upside116.97% upside

Cytokinetics (NASDAQ:CYTK) Consensus Price Target History

Price Target History for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/27/2018HC WainwrightReiterated RatingBuy$20.00HighView Rating Details
4/24/2018Cantor FitzgeraldSet Price TargetHold$10.00LowView Rating Details
2/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $18.00HighView Rating Details
2/20/2018CowenReiterated RatingBuy$11.00MediumView Rating Details
11/29/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$22.00 ➝ $12.00LowView Rating Details
11/21/2017JMP SecuritiesReiterated RatingOutperform$17.00 ➝ $13.00N/AView Rating Details
11/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$18.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$24.00N/AView Rating Details
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00MediumView Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Cytokinetics (NASDAQ:CYTK) Earnings History and Estimates Chart

Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS

Cytokinetics (NASDAQ CYTK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.52)N/AView Earnings Details
4/26/2018Q1 2018($0.50)($0.56)$5.50 million$5.27 millionViewN/AView Earnings Details
2/15/2018Q4 2017($0.71)($0.75)$4.83 million($0.02) millionViewListenView Earnings Details
10/26/2017Q3 2017($0.64)($0.60)$5.35 million$6.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.5730)($0.60)$5.28 million$3.05 millionViewListenView Earnings Details
4/27/2017Q1 2017($0.11)($0.62)$5.08 million$4.15 millionViewN/AView Earnings Details
2/16/2017Q416($0.39)$0.1640$14.10 million$33.14 millionViewListenView Earnings Details
10/27/2016Q3($0.2730)$0.74$6.67 million$59.05 millionViewListenView Earnings Details
7/28/2016Q2($0.2750)($0.29)$7.80 million$5.80 millionViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)$8.14 million$8.42 millionViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
7/29/2015Q2($0.28)($0.27)$4.00 million$6.54 millionViewListenView Earnings Details
4/30/2015Q1($0.08)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)$6.50 million$9.42 millionViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
10/30/2013Q3 2013($0.09)($0.43)$15.77 million$4.47 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.55)($0.58)$4.36 million$1.01 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.54)($0.54)$0.92 million$0.82 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.60)($0.42)ViewN/AView Earnings Details
10/30/2012Q3 2012($0.60)($0.42)ViewN/AView Earnings Details
7/31/2012Q2 2012($0.72)($0.78)ViewN/AView Earnings Details
4/26/2012Q1 2012($0.84)($0.78)ViewN/AView Earnings Details
2/2/2012Q4 2011($0.78)($0.88)ViewN/AView Earnings Details
10/27/2011Q3 2011($1.14)($0.88)ViewN/AView Earnings Details
7/28/2011Q2 2011($0.66)($1.39)ViewN/AView Earnings Details
4/27/2011Q1 2011($1.14)($1.08)ViewN/AView Earnings Details
2/14/2011Q4 2010($1.32)($1.01)ViewN/AView Earnings Details
10/28/2010Q3 2010($1.26)($1.15)ViewN/AView Earnings Details
7/28/2010Q2 2010($1.20)($1.19)ViewN/AView Earnings Details
4/29/2010Q1 2010($1.20)($1.18)ViewN/AView Earnings Details
2/3/2010Q4 2009($1.32)($1.20)ViewN/AView Earnings Details
10/28/2009Q3 2009($1.32)($0.82)ViewN/AView Earnings Details
7/29/2009Q2 2009$3.06$5.90ViewN/AView Earnings Details
4/30/2009Q1 2009($1.20)($1.24)ViewN/AView Earnings Details
2/10/2009Q4 2008($2.28)($1.31)ViewN/AView Earnings Details
10/30/2008Q3 2008($2.16)($1.67)ViewN/AView Earnings Details
7/31/2008Q2 2008($2.04)($1.87)ViewN/AView Earnings Details
4/29/2008Q1 2008($1.92)($1.69)ViewN/AView Earnings Details
1/31/2008Q4 2007($2.52)($1.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cytokinetics (NASDAQ:CYTK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 68.07%
Insider Trading History for Cytokinetics (NASDAQ:CYTK)
Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2018Robert I BlumCEOSell4,000$8.38$33,520.00183,722View SEC Filing  
4/5/2018Robert I BlumCEOSell4,000$7.52$30,080.00182,701View SEC Filing  
1/16/2018Caryn Gordon McdowellInsiderSell2,709$9.00$24,381.0015,077View SEC Filing  
11/2/2017Caryn Gordon McdowellInsiderSell4,260$12.94$55,124.4017,982View SEC Filing  
11/1/2017Fady Ibraham MalikEVPSell7,321$13.39$98,028.1947,540View SEC Filing  
11/1/2017Robert I BlumCEOSell5,000$13.51$67,550.0070,180View SEC Filing  
10/6/2017Caryn Gordon McdowellInsiderSell13,181$15.49$204,173.69View SEC Filing  
10/2/2017Robert I BlumCEOSell5,000$14.59$72,950.00View SEC Filing  
9/6/2017Caryn Gordon McdowellInsiderSell10,131$14.60$147,912.6019,801View SEC Filing  
9/1/2017Robert I BlumCEOSell5,000$14.71$73,550.0079,785View SEC Filing  
8/31/2017Bradley Paul MorganSVPSell118,330$15.00$1,774,950.0063,107View SEC Filing  
8/31/2017Santo J CostaDirectorSell5,000$15.00$75,000.005,000View SEC Filing  
8/29/2017Santo J CostaDirectorSell5,000$14.00$70,000.005,000View SEC Filing  
8/8/2017Caryn Gordon McdowellInsiderSell11,348$12.47$141,509.5621,570View SEC Filing  
8/1/2017Robert I BlumCEOSell5,000$13.79$68,950.0084,785View SEC Filing  
7/3/2017Robert I BlumCEOSell5,000$12.14$60,700.0088,385View SEC Filing  
6/1/2017Robert I BlumCEOSell5,000$13.62$68,100.0094,785View SEC Filing  
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.883,361View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.0030,000View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.0030,000View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.5010,000View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.002,883,845View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytokinetics (NASDAQ CYTK) News Headlines

Source:
DateHeadline
Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMACytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA
finance.yahoo.com - May 17 at 3:10 PM
Zacks: Brokerages Expect Cytokinetics (CYTK) Will Post Quarterly Sales of $5.57 MillionZacks: Brokerages Expect Cytokinetics (CYTK) Will Post Quarterly Sales of $5.57 Million
www.americanbankingnews.com - May 12 at 2:06 AM
Cytokinetics to Hold Annual Meeting of StockholdersCytokinetics to Hold Annual Meeting of Stockholders
finance.yahoo.com - May 11 at 5:18 AM
Zacks: Brokerages Anticipate Cytokinetics (CYTK) to Announce -$0.51 Earnings Per ShareZacks: Brokerages Anticipate Cytokinetics (CYTK) to Announce -$0.51 Earnings Per Share
www.americanbankingnews.com - May 10 at 7:19 PM
Cytokinetics (CYTK) Given Average Recommendation of "Buy" by AnalystsCytokinetics (CYTK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 1:49 PM
Robert I. Blum Sells 4,000 Shares of Cytokinetics (CYTK) StockRobert I. Blum Sells 4,000 Shares of Cytokinetics (CYTK) Stock
www.americanbankingnews.com - May 4 at 8:15 PM
Brokers Issue Forecasts for Cytokinetics FY2018 Earnings (CYTK)Brokers Issue Forecasts for Cytokinetics' FY2018 Earnings (CYTK)
www.americanbankingnews.com - May 2 at 9:42 AM
Cytokinetics (CYTK) Upgraded to Hold at BidaskClubCytokinetics (CYTK) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - April 28 at 8:34 AM
Cytokinetics (CYTK) Lifted to Hold at ValuEngineCytokinetics (CYTK) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 27 at 10:52 PM
Cytokinetics (CYTK) Posts Quarterly  Earnings Results, Misses Estimates By $0.06 EPSCytokinetics (CYTK) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - April 27 at 4:12 PM
Edited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMTEdited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMT
finance.yahoo.com - April 27 at 3:02 PM
Cytokinetics (CYTK) Given a $20.00 Price Target at HC WainwrightCytokinetics (CYTK) Given a $20.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 27 at 12:34 PM
BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.56BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.56
www.reuters.com - April 27 at 5:11 AM
Cytokinetics (CYTK) CEO Robert Blum on Q1 2018 Results - Earnings Call TranscriptCytokinetics' (CYTK) CEO Robert Blum on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 5:11 AM
Cytokinetics, Inc. Reports First Quarter 2018 Financial ResultsCytokinetics, Inc. Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 27 at 5:11 AM
Cytokinetics: 1Q Earnings SnapshotCytokinetics: 1Q Earnings Snapshot
finance.yahoo.com - April 27 at 5:11 AM
Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?
finance.yahoo.com - April 26 at 3:02 PM
Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal ...Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal ...
globenewswire.com - April 24 at 3:10 PM
Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA ConferenceCytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
finance.yahoo.com - April 24 at 3:10 PM
Cantor Fitzgerald Analysts Give Cytokinetics (CYTK) a $10.00 Price TargetCantor Fitzgerald Analysts Give Cytokinetics (CYTK) a $10.00 Price Target
www.americanbankingnews.com - April 24 at 10:28 AM
Cytokinetics (CYTK) Set to Announce Quarterly Earnings on WednesdayCytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:44 AM
Cytokinetics (CYTK) Stock Rating Upgraded by BidaskClubCytokinetics (CYTK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 16 at 10:54 AM
Cytokinetics (CYTK) Given a $26.00 Price Target at HC WainwrightCytokinetics (CYTK) Given a $26.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 13 at 7:15 PM
Cytokinetics to Announce First Quarter Results on April 26, 2018Cytokinetics to Announce First Quarter Results on April 26, 2018
globenewswire.com - April 13 at 5:03 AM
Cytokinetics to Announce First Quarter Results on April 26, 2018Cytokinetics to Announce First Quarter Results on April 26, 2018
finance.yahoo.com - April 13 at 5:03 AM
Cytokinetics (CYTK) Receives Consensus Rating of "Hold" from BrokeragesCytokinetics (CYTK) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 1:41 PM
Insider Selling: Cytokinetics, Inc. (CYTK) CEO Sells 4,000 Shares of StockInsider Selling: Cytokinetics, Inc. (CYTK) CEO Sells 4,000 Shares of Stock
www.americanbankingnews.com - April 6 at 7:33 PM
Cytokinetics (CYTK) Stock Rating Upgraded by ValuEngineCytokinetics (CYTK) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 5 at 2:09 PM
Cytokinetics (CYTK) Downgraded by TheStreetCytokinetics (CYTK) Downgraded by TheStreet
www.americanbankingnews.com - April 2 at 9:42 PM
Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMTEdited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT
finance.yahoo.com - April 1 at 5:00 AM
Cytokinetics (CYTK) Cut to "Strong Sell" at ValuEngineCytokinetics (CYTK) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 29 at 11:18 PM
Cytokinetics (CYTK) Rating Increased to Sell at BidaskClubCytokinetics (CYTK) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:11 PM
Cytokinetics, Inc. (CYTK) Given Consensus Recommendation of "Buy" by BrokeragesCytokinetics, Inc. (CYTK) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 1:48 PM
Cytokinetics Joins Global Initiative to Recognize International Rare Disease DayCytokinetics Joins Global Initiative to Recognize International Rare Disease Day
finance.yahoo.com - February 28 at 3:13 PM
Cytokinetics (CYTK) PT Raised to $18.00Cytokinetics (CYTK) PT Raised to $18.00
www.americanbankingnews.com - February 21 at 5:30 PM
Cytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by BrokeragesCytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 2:31 PM
Cytokinetics (CYTK) Earns Buy Rating from CowenCytokinetics (CYTK) Earns Buy Rating from Cowen
www.americanbankingnews.com - February 20 at 8:26 PM
Cytokinetics Sees Unusually Large Options Volume (CYTK)Cytokinetics Sees Unusually Large Options Volume (CYTK)
www.americanbankingnews.com - February 20 at 6:56 AM
Cytokinetics (CYTK) Announces  Earnings Results, Misses Estimates By $0.04 EPSCytokinetics (CYTK) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - February 16 at 11:40 AM
Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 16 at 5:10 AM
Cytokinetics reports 4Q lossCytokinetics reports 4Q loss
finance.yahoo.com - February 16 at 5:10 AM
Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial ResultsCytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - February 16 at 5:10 AM
Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 MillionCytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million
www.americanbankingnews.com - February 16 at 3:46 AM
Cytokinetics Earnings Outlook - BenzingaCytokinetics Earnings Outlook - Benzinga
www.benzinga.com - February 15 at 3:10 PM
Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 15 at 5:10 AM
Cytokinetics to Present at the RBC Capital Markets Global Healthcare ConferenceCytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 5:10 AM
 Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - February 14 at 5:16 PM
Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release)Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release)
www.globenewswire.com - February 14 at 3:09 PM
Cytokinetics (CYTK) Names Robert Califf to Board of DirectorsCytokinetics (CYTK) Names Robert Califf to Board of Directors
www.streetinsider.com - February 13 at 3:07 PM
Cytokinetics (CYTK) Hold Rating Reiterated at Cantor FitzgeraldCytokinetics' (CYTK) Hold Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - February 12 at 4:18 PM

SEC Filings

Cytokinetics (NASDAQ:CYTK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytokinetics (NASDAQ CYTK) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.